Intriguingly, the use of glucagon-like peptide 1 receptor (GLP-1) agonists, which were originally developed for the treatment of diabetes mellitus and obesity, have been shown to improve exercise capacity in patients with HFpEF [127, 128]. This evidence concerns the gene GLP1R and obesity disorder.